Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have been assigned an average rating of “Moderate Buy” from the five brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $14.2750.

Several research analysts have commented on the stock. Canaccord Genuity Group dropped their price objective on shares of Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Wall Street Zen cut shares of Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a report on Wednesday, October 8th.

Insider Buying and Selling at Niagen Bioscience

In other Niagen Bioscience news, CFO Ozan Pamir purchased 4,465 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The stock was purchased at an average cost of $6.81 per share, with a total value of $30,406.65. Following the purchase, the chief financial officer owned 7,372 shares of the company’s stock, valued at approximately $50,203.32. The trade was a 153.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.39% of the company’s stock.

Institutional Trading of Niagen Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. Silverberg Bernstein Capital Management LLC bought a new position in shares of Niagen Bioscience in the third quarter worth about $1,169,000. BSW Wealth Partners purchased a new stake in Niagen Bioscience in the 3rd quarter valued at about $793,000. CWM LLC purchased a new stake in Niagen Bioscience in the 3rd quarter valued at about $246,000. Precision Wealth Strategies LLC bought a new position in Niagen Bioscience in the 3rd quarter worth about $1,527,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of Niagen Bioscience during the third quarter worth approximately $144,000. 15.41% of the stock is currently owned by institutional investors.

Niagen Bioscience Trading Down 0.8%

NAGE opened at $6.29 on Thursday. The stock has a 50-day moving average of $6.98 and a 200 day moving average of $9.39. Niagen Bioscience has a 12 month low of $5.16 and a 12 month high of $14.69. The firm has a market cap of $502.00 million, a P/E ratio of 26.21 and a beta of 2.31.

Niagen Bioscience (NASDAQ:NAGE) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. The business had revenue of $33.99 million during the quarter, compared to analyst estimates of $31.30 million. Niagen Bioscience had a return on equity of 24.13% and a net margin of 16.38%.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.